Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Operating Leases (2019 - 2024)

Palisade Bio (PALI) has disclosed Operating Leases for 6 consecutive years, with $24000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Operating Leases fell 84.31% to $24000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $24000.0, a 84.31% decrease, with the full-year FY2023 number at $90000.0, down 57.35% from a year prior.
  • Operating Leases was $24000.0 for Q2 2024 at Palisade Bio, down from $58000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $266000.0 in Q2 2022 to a low of $24000.0 in Q2 2024.
  • A 5-year average of $148754.6 and a median of $144697.5 in 2020 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 56.09% in 2021, then plummeted 84.31% in 2024.
  • Palisade Bio's Operating Leases stood at $112000.0 in 2020, then skyrocketed by 79.46% to $201000.0 in 2021, then grew by 4.98% to $211000.0 in 2022, then plummeted by 57.35% to $90000.0 in 2023, then plummeted by 73.33% to $24000.0 in 2024.
  • Per Business Quant, the three most recent readings for PALI's Operating Leases are $24000.0 (Q2 2024), $58000.0 (Q1 2024), and $90000.0 (Q4 2023).